11/18/2021 8:10:42 AM
Kintara Presents Updates On Two Phase 2 Clinical Studies On Neuro-oncology
9/29/2021 8:10:52 AM
Kintara Therapeutics FY Loss Per Share $1.60 Vs Loss $0.87 Last Year
6/3/2021 8:02:45 AM
Kintara Therapeutics Says Enrolls Final Patient In Phase 2 Trial Of VAL-083 For Adjuvant Treatment Of Brain Tumors
5/26/2021 8:14:28 AM
Kintara Therapeutics Provides Positive Site Activation Update On GCAR Phase 2/3 Clinical Trial For Glioblastoma
5/14/2021 8:35:39 AM
Amended: Kintara Therapeutics Q3 Loss Per Share $0.23 Vs Loss Per Share $0.17 Last Year
5/4/2021 8:27:54 AM
Kintara Therapeutics Appoints Tamara Seymour To Board
4/12/2021 8:23:44 AM
Kintara Presents Interim Data Results On Two Phase 2 Clinical Trials Of VAL-083 At AACR Annual Meeting
2/17/2021 8:24:55 AM
Kintara Therapeutics Enrolls Final Patient In Phase 2 Clinical Trial Of VAL-083 For Recurrent GBM
1/13/2021 8:14:51 AM
Kintara Initiates Patient Recruitment For VAL-083's Study Arm In GBM AGILE Trial
11/13/2020 8:06:50 AM
Kintara Therapeutics Q1 Net Loss $19.5 Mln Or $1.33/shr Vs. Net Loss Of $1.6 Mln Or $0.21/shr Prior Year
10/21/2020 8:22:07 AM
Kintara,e Global Coalition For Adaptive Research Execute Agreement For VAL-083's Participation In GBM AGILE Study